Standardized reporting systems for computed tomography coronary angiography and calcium scoring: A real-world validation of CAD-RADS and CAC-DRS in patients with stable chest pain

Citation for published version:

Digital Object Identifier (DOI):
10.1016/j.jcct.2019.07.010

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Version created as part of publication process; publisher's layout; not normally made publicly available

Published In:
Journal of Cardiovascular Computed Tomography

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Research paper

Standardized reporting systems for computed tomography coronary angiography and calcium scoring: A real-world validation of CAD-RADS and CAC-DRS in patients with stable chest pain

Michelle C. Williamsa,b,∗, Alastair Mossa, Marc Dwecka, Amanda Huntera, Tania Pawadea, Philip Adamsonh,c, Anoop.S.V. Shahh, Shirjel Alamh, Christopher D. Maroulesd, Edwin JR. van Beekb, Ricardo Curye, Edward D. Newbya,b, Giles Ruditihi

a University of Edinburgh/British Heart Foundation Centre for Cardiovascular Science, Edinburgh, UK
b Edinburgh Imaging Facility QMRI, University of Edinburgh, Edinburgh, UK
c Christchurch Heart Institute, University of Otago, Christchurch, New Zealand
d Department of Radiology, Naval Medical Center, Portsmouth, VA, USA
h Miami Cardiac and Vascular Institute, Baptist Health of South Florida, Miami, FL, USA
i Royal Brompton and Harefield NHS Foundation Trust Departments of Cardiology and Radiology, London, UK
j National Heart and Lung Institute, Faculty of Medicine, Imperial College, London, UK
k Glasgow Clinical Research Imaging Facility, Queen Elizabeth University Hospital, Glasgow, Scotland, UK

ARTICLE INFO

Keywords:
Computed tomography
Computed tomography coronary angiography
Chest pain
Angina
Standardized reporting

ABSTRACT

Objectives: To assess the prognostic implications of standardized reporting systems for coronary computed tomography angiography (CCTA) and coronary artery calcium scores (CACS) in patients with stable chest pain.

Background: The Coronary Artery Disease Reporting And Data System (CAD-RADS) and Coronary Artery Calcium – Data and Reporting System (CAC-DRS) aim to improve communication of CACS and CCTA results, but its influence on prognostication is unknown.

Methods: Images from 1769 patients who underwent CCTA as part of the Scottish Computed Tomography of the HEART (SCOT-HEART) multi-center randomized controlled trial were assessed. CACS were classified as CAC-DRS 0 to 3 based on Agatston scores. CCTA were classified as CAD-RADS 0 to 5 based on the most clinically relevant finding per patient. The primary outcome was the five-year events of fatal and non-fatal myocardial infarction.

Results: Patients had a mean age of 58 ± 10 years and 56% were male. CAC-DRS 0, 1, 2 and 3 occurred in 642 (36%), 510 (29%), 379 (21%) patients respectively. CAD-RADS 0, 1, 2, 3, 4A, 4B and 5 occurred in 622 (35%), 327 (18%), 211 (12%), 165 (9%), 221 (12%), 42 (2%) and 181 (10%) patients respectively. Patients classified as CAC-DRS 3 were at an increased risk of fatal or non-fatal myocardial infarction compared to CAC-DRS 0 patients (hazard ratio (HR) 9.41; 95% confidence interval (CI) 3.24, 27.31; p < 0.001). Patients with higher CAD-RADS categories were at an increased risk of fatal or non-fatal myocardial infarction, with patients classified as CAD-RADS 4B at the highest risk compared to CAD-RADS 0 patients (HR 19.14; 95% CI 4.28, 85.53; p < 0.001).

Conclusion: Patients with higher CAC-DRS and CAD-RADS scores were at increased risk of subsequent fatal and non-fatal myocardial infarction. This confirms that the classification provides additional prognostic discrimination for future coronary heart disease events.

1. Introduction

Standardized reporting systems aim to improve the communication of results to referring physicians and provide consistent reporting, in order to aid quality assurance, education, research and peer-review. Recently standardized reporting systems have been developed for

* Corresponding author. University/BHF Centre for Cardiovascular Science, Chancellor’s Building, SU305, 49 Little France Crescent, Edinburgh, EH16SUF, UK.
E-mail address: michelle.williams@ed.ac.uk (M.C. Williams).
https://doi.org/10.1016/j.jcct.2019.07.010

Received 22 April 2019; Received in revised form 9 July 2019; Accepted 24 July 2019

1934-5925/ © 2019 The Author. Published by Elsevier Inc. on behalf of Society of Cardiovascular Computed Tomography This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).

https://doi.org/10.1016/j.jcct.2019.07.010

Please cite this article as: Michelle C. Williams, et al., Journal of Cardiovascular Computed Tomography, https://doi.org/10.1016/j.jcct.2019.07.010
coronary artery calcium scoring (CACS). However, their clinical relevance for prognosis is currently unknown.

The Coronary Artery Disease – Reporting And Data System (CAD-RADS) classifies patients based on the highest grade of coronary artery stenosis on CCTA, ranging from a score of zero for normal coronary arteries to 5 for patients with at least one occluded coronary artery (Table 1). The CAD-RADS system also includes additional modifiers for the presence of vulnerable plaque (V), grafts (G) and stents (S). The Coronary Artery Calcium – Data and Reporting System (CAC-DRS) classifies patients based on either visual or quantitative assessment of coronary artery calcification (Table 1). These scoring systems provide a simple method to indicate the overall severity of disease to the referring physician. Alongside disease severity, they also provide standardized recommendations for subsequent management and investigation for each category.

The Scottish Computed Tomography of the HEART (SCOT-HEART) trial is a large prospective multi-center randomized controlled trial that assessed the use of CCTA in patients with suspected angina due to coronary artery disease. It showed that management based on CCTA improves diagnostic certainty and reduced the rate of coronary heart disease death and non-fatal myocardial infarction. This post-hoc analysis of the SCOT-HEART trial aimed to assess the distribution of CAD-RADS and CAC-DRS groups within the SCOT-HEART population and to assess subsequent clinical outcomes.

2. Methods

2.1. Study design

The SCOT-HEART trial was a multicenter randomized controlled trial investigating the use of CCTA in patients with suspected angina due to coronary artery disease. The primary results of the SCOT-HEART study have been published previously.

2.2. Participants

In the SCOT-HEART study, 4146 patients attending cardiology outpatient clinics with stable chest pain were randomized to standard care or standard care plus CCTA. Of these participants, 2073 were randomized to the intervention arm, and 1778 of these subsequently underwent non-contrast electrocardiogram-gated computed tomography (CT) for calcium scoring and CCTA as described previously. Cardiovascular risk was calculated using the ASSIGN (Assessing cardiovascular risk using SIGN guidelines) cardiovascular risk score as previously described.

2.3. CAC-DRS reporting system

In the SCOT-HEART trial, coronary artery calcium score was assessed using the Agatston scoring system as described previously. In the current study, each participant was assigned a CAC-DRS category based on their previously calculated Agatston score (Table 1).

2.4. CAD-RADS reporting system

As the classification of the CAD-RADS system differed from the assessment of CCTA in the SCOT-HEART trial, all CCTA were reviewed and recategorized according to CAD-RADS based on the most severe stenosis (Table 1). The CAD-RADS V modifier was assigned to patients with one or more plaques with two or more high-risk features, including low attenuation plaque (< 30 Hounsfield Units), positive remodelling, spotty calcification or the “napkin ring” sign.

2.5. Outcomes

Outcome information was obtained in March 2018 from the electronic Data Research and Innovation Service (eDRIS) of the National Health Service (NHS) Scotland and confirmed by review of the patient health records where required. The primary event for this sub-study was the occurrence of coronary heart disease death or non-fatal myocardial infarction.

2.6. Statistical analysis

Statistical analysis was performed using R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria). Quantitative data are presented as mean and standard deviation or, if not normally distributed, as median and interquartile range. Statistical significance was assessed using Student t-test, Mann-Whitney U test, analysis of variance, Chi-square test or Fisher’s exact test as appropriate. Hazard ratios (HR) and 95% confidence intervals (CI) are presented. Regression analysis was performed to assess the effect of cardiovascular risk factors on CAC-DRS and CAD-RADS scores. Variables which were statistically significant on univariate analysis were included in multivariate analysis. Outcome data were analyzed using Cox proportional hazards regression and presented graphically using cumulative incidence plots. Due to small number of events, CAD-RADS categories 2 and 3, and 4 and 5 were combined. A statistically significant difference was defined as a two-sided P value < 0.05.

3. Results

3.1. Patient demographics

Of the 1778 who underwent CT, there were 1769 CT images which were of suitable image quality for analysis. Patients had a mean age of 58 ± 10 years and 56% were male (Table 2). The primary event of
coronary heart disease death or non-fatal myocardial infarction occurred in 41 patients (2.3%) over a median follow-up of 4.7 years (interquartile range [IQR], 4.0 to 5.7).

### 3.2. CAC-DRS

The median CAC score was 21 Agatston units [IQR] 0, 230] and the most frequent classifications were CAC-DRS 0 (36%) or 1 (29%) (Table 2). Patients with higher CAC-DRS classifications were more likely to be older male ex-smokers, and have typical angina, a higher cardiovascular risk score, hypertension, diabetes, a slightly lower total cholesterol, and a history of previous coronary artery or cerebrovascular disease (Table 2). In the multivariate model, age, gender, smoking status, chest pain symptoms, and history of previous coronary heart disease, were independent predictors of a higher CAC-DRS classification.

### 3.3. CAD-RADS

The most frequent CAD-RADS classification was 0 (normal coronary arteries) occurring in 622 patients (35%, Table 3). Of the 642 patients who were CAC-DRS 0, there were 112 (17%) who were categorised as CAD-RADS 1 or above. Patients with higher CAD-RADS classification were more likely to be older male non-smokers and have typical angina, previous coronary heart disease, hypertension, diabetes, and a higher cardiovascular risk score. In the multivariate model, age, gender, smoking status, chest pain symptoms, previous history of coronary heart disease and cardiovascular risk score remained independent predictors of a higher CAD-RADS classification. CADRADS V was identified in 201 patients (11%) and was more frequent in patients with a higher CAD-RADS score (Fig. 1; P < 0.001).

### 3.4. Medications and revascularisation

Prescription of preventative medications at 6 weeks and increased

---

### Table 2

Demographic information for CAC-DRS subgroups.

<table>
<thead>
<tr>
<th>CAC-DRS</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>1769</td>
<td>642 (36)</td>
<td>509 (29)</td>
<td>239 (14)</td>
</tr>
<tr>
<td>Male</td>
<td>997 (56)</td>
<td>250 (39)</td>
<td>276 (54)</td>
<td>162 (68)</td>
</tr>
<tr>
<td>Age</td>
<td>58 ± 10</td>
<td>53 ± 10</td>
<td>58 ± 9</td>
<td>61 ± 8</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>30 ± 6</td>
<td>30 ± 6</td>
<td>30 ± 6</td>
<td>29 ± 4</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>34 (2)</td>
<td>12 (2)</td>
<td>8 (2)</td>
<td>4 (2)</td>
</tr>
<tr>
<td>Previous coronary heart disease</td>
<td>178 (10)</td>
<td>21 (3)</td>
<td>28 (6)</td>
<td>32 (13)</td>
</tr>
<tr>
<td>Previous cerebrovascular disease</td>
<td>79 (4)</td>
<td>16 (2)</td>
<td>22 (4)</td>
<td>15 (6)</td>
</tr>
<tr>
<td>Previous peripheral vascular disease</td>
<td>31 (2)</td>
<td>6 (1)</td>
<td>8 (2)</td>
<td>4 (2)</td>
</tr>
<tr>
<td>Smoking status</td>
<td>Current smoker</td>
<td>330 (19)</td>
<td>127 (20)</td>
<td>99 (19)</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>593 (34)</td>
<td>164 (26)</td>
<td>168 (33)</td>
<td>82 (34)</td>
</tr>
<tr>
<td>Non-smoker</td>
<td>845 (48)</td>
<td>350 (55)</td>
<td>242 (48)</td>
<td>102 (43)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>608 (35)</td>
<td>153 (24)</td>
<td>175 (35)</td>
<td>85 (36)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>196 (11)</td>
<td>44 (7)</td>
<td>63 (12)</td>
<td>26 (11)</td>
</tr>
<tr>
<td>Family history</td>
<td>765 (44)</td>
<td>279 (44)</td>
<td>230 (45)</td>
<td>104 (44)</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>192 ± 73</td>
<td>196 ± 68</td>
<td>197 ± 72</td>
<td>189 ± 80</td>
</tr>
<tr>
<td>Anginal symptoms</td>
<td>Typical angina</td>
<td>654 (37)</td>
<td>148 (23)</td>
<td>185 (36)</td>
</tr>
<tr>
<td>Atypical angina</td>
<td>432 (24)</td>
<td>178 (28)</td>
<td>117 (23)</td>
<td>70 (29)</td>
</tr>
<tr>
<td>Non-anginal</td>
<td>683 (39)</td>
<td>316 (49)</td>
<td>207 (41)</td>
<td>73 (31)</td>
</tr>
<tr>
<td>ASSIGN cardiovascular risk score</td>
<td>18 ± 11</td>
<td>12 ± 9</td>
<td>19 ± 11</td>
<td>22 ± 11</td>
</tr>
</tbody>
</table>

Number and (percentage). * p < 0.05.

### Table 3

Demographic information for CAD-RADS subgroups.

<table>
<thead>
<tr>
<th>CAD-RADS</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4A</th>
<th>4B</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>622 (35)</td>
<td>327 (18)</td>
<td>211 (12)</td>
<td>165 (9)</td>
<td>221 (12)</td>
<td>42 (2)</td>
<td>181 (10)</td>
</tr>
<tr>
<td>Male</td>
<td>252 (41)</td>
<td>173 (53)</td>
<td>126 (60)</td>
<td>105 (64)</td>
<td>160 (72)</td>
<td>32 (76)</td>
<td>149 (82) *</td>
</tr>
<tr>
<td>Age</td>
<td>53 ± 10</td>
<td>58 ± 8</td>
<td>60 ± 9</td>
<td>64 ± 8</td>
<td>61 ± 8</td>
<td>62 ± 8</td>
<td>62 ± 8 *</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>30 ± 6</td>
<td>29 ± 5</td>
<td>29 ± 5</td>
<td>30 ± 5</td>
<td>29 ± 5</td>
<td>30 ± 5</td>
<td>30 ± 5</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>12 (2)</td>
<td>5 (2)</td>
<td>3 (1)</td>
<td>5 (3)</td>
<td>6 (3)</td>
<td>1 (2)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Previous coronary heart disease</td>
<td>18 (3)</td>
<td>16 (5)</td>
<td>34 (16)</td>
<td>23 (14)</td>
<td>30 (14)</td>
<td>10 (24)</td>
<td>47 (26) *</td>
</tr>
<tr>
<td>Previous cerebrovascular disease</td>
<td>15 (2)</td>
<td>15 (5)</td>
<td>13 (6)</td>
<td>11 (7)</td>
<td>17 (8)</td>
<td>1 (2)</td>
<td>7 (4)</td>
</tr>
<tr>
<td>Previous peripheral vascular disease</td>
<td>7 (1)</td>
<td>4 (1)</td>
<td>4 (2)</td>
<td>2 (1)</td>
<td>6 (3)</td>
<td>4 (10)</td>
<td>4 (2)</td>
</tr>
<tr>
<td>Smoking status</td>
<td>Current smoker</td>
<td>112 (18)</td>
<td>58 (18)</td>
<td>47 (22)</td>
<td>27 (16)</td>
<td>45 (20)</td>
<td>8 (19)</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>168 (27)</td>
<td>108 (33)</td>
<td>84 (40)</td>
<td>71 (43)</td>
<td>77 (35)</td>
<td>21 (50)</td>
<td>64 (35) *</td>
</tr>
<tr>
<td>Non-smoker</td>
<td>341 (55)</td>
<td>161 (49)</td>
<td>80 (38)</td>
<td>67 (41)</td>
<td>99 (45)</td>
<td>13 (31)</td>
<td>84 (46) *</td>
</tr>
<tr>
<td>Hypertension</td>
<td>155 (25)</td>
<td>111 (34)</td>
<td>69 (33)</td>
<td>74 (45)</td>
<td>27 (14)</td>
<td>16 (39)</td>
<td>79 (39)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>51 (8)</td>
<td>43 (13)</td>
<td>21 (10)</td>
<td>22 (13)</td>
<td>23 (11)</td>
<td>3 (7)</td>
<td>32 (18) *</td>
</tr>
<tr>
<td>Family history</td>
<td>273 (44)</td>
<td>148 (45)</td>
<td>92 (44)</td>
<td>66 (41)</td>
<td>101 (46)</td>
<td>21 (50)</td>
<td>64 (36)</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>194 ± 73</td>
<td>196 ± 73</td>
<td>178 ± 83</td>
<td>192 ± 67</td>
<td>189 ± 75</td>
<td>195 ± 73</td>
<td>199 ± 77</td>
</tr>
<tr>
<td>Anginal symptoms</td>
<td>Typical angina</td>
<td>152 (24)</td>
<td>87 (27)</td>
<td>66 (31)</td>
<td>61 (37)</td>
<td>131 (59)</td>
<td>24 (57)</td>
</tr>
<tr>
<td>Atypical angina</td>
<td>163 (26)</td>
<td>89 (27)</td>
<td>59 (28)</td>
<td>42 (25)</td>
<td>42 (21)</td>
<td>5 (2)</td>
<td>24 (13) *</td>
</tr>
<tr>
<td>Non-anginal</td>
<td>307 (49)</td>
<td>151 (46)</td>
<td>86 (41)</td>
<td>62 (38)</td>
<td>44 (20)</td>
<td>9 (21)</td>
<td>24 (13) *</td>
</tr>
<tr>
<td>ASSIGN cardiovascular risk score</td>
<td>12.4 ± 8.7</td>
<td>18.7 ± 11.1</td>
<td>19.7 ± 10.8</td>
<td>20.5 ± 10.1</td>
<td>22.8 ± 10.7</td>
<td>21.2 ± 10.4</td>
<td>24.3 ± 11.6 *</td>
</tr>
</tbody>
</table>

Number and (percentage). * p < 0.05.

---

M.C. Williams, et al.  
Journal of Cardiovascular Computed Tomography xxx (xxxx) xxx–xxx
use of coronary revascularisation was associated with higher CAC-DRS and CAD-RADS classification groups (p < 0.001 for both, Table 4, Fig. 2). When comparing patients with a CAD-RADS classification of 4 or 5 to patients with CAD-RADS classification of 1, the odds ratio for preventative medication use and coronary revascularisation were 7.06 (95% CI, 4.42 to 11.70, p < 0.001) and 42.15 (95% CI, 20.98 to 100.48, p < 0.001) respectively.

3.5. Clinical outcomes

Patients in the highest CAC-DRS category were at an increased risk of coronary heart disease death or non-fatal myocardial infarction compared to those with CAC-DRS 0 (Table 4, Fig. 3). Similarly, patients with a higher CAD-RADS classification were at an increased risk of coronary heart disease death or non-fatal myocardial infarction (Table 4, Fig. 4). Patients in CAD-RADS group 4B were at the highest risk (Hazard ratio (HR) 19.14 (95% CI 4.28, 85.53), p = 0.0001), but

Table 4
Medication use, revascularisation and subsequent outcomes in (A) CAC-DRS and (B) CAD-RADS subgroups.

<table>
<thead>
<tr>
<th>CAC-DRS</th>
<th>Preventative medications at 6 weeks</th>
<th>Revascularisation</th>
<th>CHD death or non-fatal myocardial infarction&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (%)</td>
<td></td>
<td>Hazard ratio&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>0</td>
<td>282 (44%)</td>
<td>7 (1%)</td>
<td>4 (1%)</td>
</tr>
<tr>
<td>1</td>
<td>370 (73%)</td>
<td>45 (9%)</td>
<td>10 (2%)</td>
</tr>
<tr>
<td>2</td>
<td>211 (88%)</td>
<td>53 (22%)</td>
<td>5 (2%)</td>
</tr>
<tr>
<td>3</td>
<td>352 (93%)</td>
<td>145 (38%)</td>
<td>22 (6%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAD-RADS</td>
<td>Preventative medications at 6 weeks</td>
<td>Revascularisation</td>
<td>CHD death or non-fatal myocardial infarction&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>N (%)</td>
<td></td>
<td>Hazard ratio&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>0</td>
<td>243 (39%)</td>
<td>0</td>
<td>3 (1%)</td>
</tr>
<tr>
<td>1</td>
<td>236 (72%)</td>
<td>7 (2%)</td>
<td>7 (2%)</td>
</tr>
<tr>
<td>2</td>
<td>170 (81%)</td>
<td>13 (6%)</td>
<td>4 (2%)</td>
</tr>
<tr>
<td>3</td>
<td>145 (88%)</td>
<td>17 (10%)</td>
<td>7 (4%)</td>
</tr>
<tr>
<td>4A</td>
<td>299 (95%)</td>
<td>94 (43%)</td>
<td>8 (4%)</td>
</tr>
<tr>
<td>4B</td>
<td>41 (98%)</td>
<td>19 (45%)</td>
<td>4 (10%)</td>
</tr>
<tr>
<td>5</td>
<td>171 (94%)</td>
<td>100 (55%)</td>
<td>8 (4%)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Compared to patients with CAC-DRS 0.
<sup>b</sup> Compared to patients with CAD-RADS 0.
<sup>c</sup> Hazard ratio and 95% confidence interval. Number (percentage).
there was overlap between CAD-RADS categories 3 to 5 (Supplementary Fig. 1). We did not identify any difference in the rate of coronary heart disease death or non-fatal myocardial infarction in patients with or without the CAD-RADS V modifier (HR 1.59 (95% CI 0.70, 3.58), p = 0.266; Fig. 5).

4. Discussion

CAC-DRS and CAD-RADS stratify patients across the range of coronary artery disease, management and subsequent outcomes, with some overlap between the groups in terms of 5-year outcomes. Patients with low CAC-DRS or CAD-RADS scores have a very small, but not zero, risk of subsequent cardiac events. In contrast, those in the highest CAC-DRS and CAD-RADS categories were greater than 9 times more likely to suffer coronary heart disease death or non-fatal myocardial infarction than those with the lowest score.

CAC-DRS and CAD-RADS both follow a tradition of reporting and data systems used to classify the probability of cancer based on imaging findings.9–13 These systems aim to improve the communication of results to clinicians, to provide recommendations for further management and to enhance research and audit. CAC-DRS and CAD-RADS mark a departure from the use of these systems in cancer imaging and applies the same structured reporting system to coronary artery disease. In classifying disease based on the most severe stenosis, CAD-RADS is also different to other CCTA scoring systems which quantified disease across the entire coronary tree.14 In our study both CAC-DRS and CAD-RADS successfully identify patients in the lowest risk groups, but there was overlap in terms of management and outcomes in the other groups.

Multiple studies have shown the prognostic value of coronary artery calcification and its additive value to traditional risk factors for predicting the presence of coronary artery disease or subsequent cardiac events.15–20 In the PROMISE study, a cut-off of 400 Agatston units identified patients with increased risk of cardiovascular death or myocardial infarction with an adjusted hazard ratio of 1.92 (95% CI 0.84, 4.39).21 Similarly in the SCOT-HEART study, increased coronary artery calcium score was associated with an increased risk of coronary heart disease death or non-fatal myocardial infarction.22 The CAC-DRS classification uses an upper limit of 300 Agatston units, potentially underestimating the increased risk of even higher coronary artery calcium score. Similar to previous studies, patients with no coronary artery calcification were at a lower, but not absent, risk of cardiac events.21,23,24 Indeed, CCTA identified at-risk patients with plaque disease but a calcium score of zero. Thus, coronary artery calcification alone may lack sufficient sensitivity for the diagnosis of patients with suspected angina due to coronary heart disease.

Patients classified as CAD-RADS 4B were at the highest risk of subsequent events. These patients had left main stem stenosis >50% or 3 vessel disease ≥70%. This is in keeping with other studies which have shown that the presence of obstructive coronary artery disease is associated with a poorer prognosis.25–27 In the CONFIRM registry (CORonary CT Angiography Evaluation For Clinical Outcomes: An InTerNational Multicenter) increasing CAD-RADS scores were associated with an increased risk of death or myocardial infarction up to a hazard ratio of 6.09 (95% CI 4.34 to 8.54) for patients with CAD-RADS 5. However, CAD-RADS classifications based on a single stenosis may merely be a surrogate marker of overall plaque burden. Indeed, it must be remembered that most myocardial infarctions occur in segments without previous obstructive coronary artery disease.28–30 Moreover,
Fig. 3. Cumulative incidence curve of coronary heart disease (CHD) death or non-fatal myocardial infarction (MI) for patients with different CAC-DRS classifications.

Fig. 4. Cumulative incidence curve of coronary heart disease (CHD) death or non-fatal myocardial infarction (MI) with different CAD-RADS classifications.
patients with borderline obstructive disease in our study (CAD-RADS 3, 50–69%) had event rates that were similar to those with critical or occluded vessels. This is consistent with previous historical data demonstrating that 5-year myocardial infarction rates plateau above coronary stenoses of > 50%. This finding may be because these CAD-RADS 3 patients had a heavy burden of atherosclerotic plaque despite the absence of obstructive disease, or because underlying characteristics of their plaque or phenotype puts them at a greater risk of subsequent coronary events. The factors contributing to myocardial infarction in patients without pre-existing obstructive coronary artery disease warrants further investigation. In addition, this highlights that there are subgroups of patients with non-obstructive coronary artery disease who are at increased risk of cardiac events, and who may benefit from more aggressive therapy.

The CAD-RADS V modifier was applied to 11% of patients in this study, similar to the rate of high risk plaques identified in other studies. Interestingly, we did not identify an increased risk associated with the CAD-RADS V modifier, despite other definitions of adverse plaque being associated with an increased risk in the SCOT-HEART population. In particular, the inclusion of spotty calcification in the CAD-RADS V classification reduces the specificity of this modifier. The definition of high risk plaque varies between studies. Using the CAD-RADS definition of adverse plaque retrospectively did not identify patients who subsequently experienced adverse events. However, an alternative definition, using only the presence of positive remodelling or low attenuation plaque, identified patients at increased risk of coronary heart disease death or non-fatal myocardial infarction in the SCOT-HEART population. An additional issue for the clinical use of the CAD-RADS V classification is the considerable observer variability in the classification of potentially “vulnerable” plaques. Interobserver reproducibility of the CAD-RADS system was found to be excellent, apart from the CAD-RADS V modifier which demonstrated only fair agreement. Therefore, the CAD-RADS V modifier must be used with caution and that an alternative definition should be considered. Further standardization with quantitative assessment may provide a more reliable definition.

The application of a system that originally was used to qualify a cancer diagnosis to coronary artery disease does have some limitations. First, the results of the CT scan can be summarized with a single classification based on the most severe disease in a single vessel. This has the potential to underestimate the severity of multi-vessel disease, especially when there is a large burden of non-obstructive disease. More nuanced findings on CCTA also have the potential to be missed if only the CAD-RADS classification is communicated to the referrer. In particular, the increased risk of subsequent fatal or non-fatal myocardial infarction in a subset of CAD-RADS 3 patients (50–69% stenosis) must be remembered and appropriately investigated and treated. The CAD-RADS classification should therefore be considered in combination with the overall scan report and its conclusions.

The main limitation of this study is that the CAD-RADS system was applied retrospectively to the SCOT-HEART dataset. To date, the prospective use of this classification system has not been assessed. Similarly, no prospective data are available on management strategies based on the identification of vulnerable plaque features. Nevertheless, this study provides an interesting insight into the way in which CACDRS and CAD-RADS classify a population with suspected angina due to coronary artery disease and the potential outcomes in each group of patients. In addition, the number of events that have occurred in this low to intermediate risk population is small, particularly when split between the subgroups. This precludes comparisons between every
References


